BR112019003175A2 - métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica. - Google Patents

métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica.

Info

Publication number
BR112019003175A2
BR112019003175A2 BR112019003175-8A BR112019003175A BR112019003175A2 BR 112019003175 A2 BR112019003175 A2 BR 112019003175A2 BR 112019003175 A BR112019003175 A BR 112019003175A BR 112019003175 A2 BR112019003175 A2 BR 112019003175A2
Authority
BR
Brazil
Prior art keywords
protein
self
methods
bioanalytical
associate
Prior art date
Application number
BR112019003175-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Marlow Michael
Sennett Michael
Schneider Michael
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of BR112019003175A2 publication Critical patent/BR112019003175A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587Nanoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
BR112019003175-8A 2016-08-18 2017-08-18 métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica. BR112019003175A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376788P 2016-08-18 2016-08-18
US62/376788 2016-08-18
PCT/US2017/047630 WO2018035470A1 (en) 2016-08-18 2017-08-18 Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy

Publications (1)

Publication Number Publication Date
BR112019003175A2 true BR112019003175A2 (pt) 2019-06-18

Family

ID=59746357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003175-8A BR112019003175A2 (pt) 2016-08-18 2017-08-18 métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica.

Country Status (19)

Country Link
US (3) US11428695B2 (https=)
EP (2) EP3500856B1 (https=)
JP (3) JP6959327B2 (https=)
KR (3) KR102717462B1 (https=)
CN (2) CN115468919A (https=)
AU (2) AU2017313150B2 (https=)
BR (1) BR112019003175A2 (https=)
CA (3) CA3254461A1 (https=)
DK (2) DK3500856T3 (https=)
EA (1) EA201990316A1 (https=)
ES (2) ES2837093T3 (https=)
FI (1) FI3761035T3 (https=)
HU (2) HUE052805T2 (https=)
IL (2) IL264640B2 (https=)
MX (2) MX2019001930A (https=)
PL (2) PL3500856T3 (https=)
SG (1) SG11201900895QA (https=)
WO (1) WO2018035470A1 (https=)
ZA (1) ZA201901035B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11428695B2 (en) 2016-08-18 2022-08-30 Regeneron Pharmaceuticals, Inc. Concentration-dependent self-interaction assay

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN113588582B (zh) * 2020-04-30 2024-05-14 上海药明生物技术有限公司 蛋白质样品浓度测定方式选择法及测定方法
WO2023095154A1 (en) * 2021-11-24 2023-06-01 Sensoville Biotech Pvt Ltd Method for determining changes in a protein's structure
WO2023141319A1 (en) * 2022-01-24 2023-07-27 Amgen Inc. Methods for detecting antibody self-association
CN119832975A (zh) * 2024-12-24 2025-04-15 上海药明生物技术有限公司 一种蛋白质共处方制剂的稳定性预测方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US771997A (en) 1903-11-21 1904-10-11 Alfred Palm Lathe attachment.
US4254102A (en) * 1975-09-08 1981-03-03 Plough, Inc. Substantive PABA compositions
US4080264A (en) 1976-03-01 1978-03-21 Massachusetts Institute Of Technology Immunoassay by light scattering spectroscopy
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20050214356A1 (en) * 2004-03-24 2005-09-29 Joyce Timothy H Self assembling activation agents targeted using active drug release
US20050221507A1 (en) * 2004-03-30 2005-10-06 Intel Corporation Method to detect molecular binding by surface-enhanced Raman spectroscopy
US7514938B2 (en) 2004-05-11 2009-04-07 Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno Dielectric relaxation spectroscopy apparatus and methods of use
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
CN101238141B (zh) * 2005-05-02 2016-10-12 巴斯福股份公司 灵敏检测分析物的新标记策略
WO2007121363A2 (en) 2006-04-13 2007-10-25 Mississippi State University An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
GB0621050D0 (en) * 2006-10-23 2006-11-29 Univ Strathclyde Functionalised polymers for labelling metal surfaces
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US20090104114A1 (en) * 2007-09-21 2009-04-23 Cytimmune Sciences, Inc. Nanotherapeutic Colloidal Metal Compositions and Methods
US20110305765A1 (en) * 2008-11-21 2011-12-15 Board Of Regents, The University Of Texas System Preparation and methodology of silk fibroin nanoparticles
US20140024024A1 (en) * 2012-07-17 2014-01-23 General Electric Company Methods of detecting dna, rna and protein in biological samples
WO2014192937A1 (ja) * 2013-05-30 2014-12-04 公立大学法人大阪府立大学 被検出物質の検出装置および方法
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP2902503A1 (en) * 2014-01-31 2015-08-05 Fundación Imdea Nanociencia Functionalized metal nanoparticles and uses thereof for detecting nucleic acids
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
CN104062287B (zh) 2014-07-01 2017-08-08 福建工程学院 一种基于纳米金催化的化学发光分析检测铁蛋白的方法
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
DK3500856T3 (da) 2016-08-18 2020-12-14 Regeneron Pharma Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11428695B2 (en) 2016-08-18 2022-08-30 Regeneron Pharmaceuticals, Inc. Concentration-dependent self-interaction assay
US11988668B2 (en) 2016-08-18 2024-05-21 Regeneron Pharmaceuticals, Inc. Concentration-dependent self-interaction assay

Also Published As

Publication number Publication date
US20240280582A1 (en) 2024-08-22
SG11201900895QA (en) 2019-02-27
DK3761035T3 (da) 2024-03-11
JP2019532267A (ja) 2019-11-07
EP3761035A1 (en) 2021-01-06
IL264640B1 (en) 2023-11-01
AU2017313150B2 (en) 2023-09-14
US11428695B2 (en) 2022-08-30
JP6959327B2 (ja) 2021-11-02
MX2023013583A (es) 2023-11-30
IL307435A (en) 2023-12-01
CA3254460A1 (en) 2025-07-03
ZA201901035B (en) 2024-06-26
US20190187149A1 (en) 2019-06-20
EA201990316A1 (ru) 2019-07-31
KR20190039185A (ko) 2019-04-10
WO2018035470A9 (en) 2018-07-05
CN115468919A (zh) 2022-12-13
EP3500856A1 (en) 2019-06-26
JP2023139189A (ja) 2023-10-03
ES2837093T3 (es) 2021-06-29
CA3254461A1 (en) 2025-07-03
EP3761035B1 (en) 2024-02-14
JP2022008959A (ja) 2022-01-14
DK3500856T3 (da) 2020-12-14
WO2018035470A1 (en) 2018-02-22
CA3032361C (en) 2025-07-08
HUE066064T2 (hu) 2024-07-28
MX2019001930A (es) 2019-07-04
JP7321227B2 (ja) 2023-08-04
CA3032361A1 (en) 2018-02-22
AU2017313150A1 (en) 2019-02-21
US11988668B2 (en) 2024-05-21
IL264640B2 (en) 2024-03-01
CN109661577B (zh) 2022-09-27
KR102534506B1 (ko) 2023-05-30
CN109661577A (zh) 2019-04-19
PL3761035T3 (pl) 2024-06-24
KR20220126801A (ko) 2022-09-16
ES2974961T3 (es) 2024-07-02
PL3500856T3 (pl) 2021-04-19
KR102717462B1 (ko) 2024-10-16
KR20230074614A (ko) 2023-05-30
HUE052805T2 (hu) 2021-05-28
AU2023274236A1 (en) 2023-12-21
EP3500856B1 (en) 2020-10-07
FI3761035T3 (fi) 2024-03-18
US20220357335A1 (en) 2022-11-10
IL264640A (https=) 2019-04-30
KR102441221B1 (ko) 2022-09-07

Similar Documents

Publication Publication Date Title
BR112019003175A2 (pt) métodos para determinar o potencial de uma proteína para se auto-associar e para preparar uma formulação farmacêutica de baixa viscosidade contendo uma proteína, e, mistura bioanalítica.
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
CL2018003178A1 (es) Composición farmacéutica
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
BR112016014756A8 (pt) formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112015031883A2 (pt) anti-pd-1 anticorpo e o uso dele
BR112019009038A2 (pt) processo p para a cetonização descarboxilativa de ácidos graxos, método m para a preparação de pelo menos um composto final de pelo menos uma cetona interna, e, uso de um intermediário de cetona interna.
BR112013025815A2 (pt) sistema e método para dimensionamento de lotes de misturas de tinturas para cabelo
BR112017010078A2 (pt) composições, dispositivos e métodos de teste de sensibilidade de ibs
BR112018014026A2 (pt) composição líquida compreendendo um polímero múltiplas fases, seu método de preparação e uso
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
BR112018012183A2 (pt) composição cosmética e seu uso, formulação cosmética
BR112017004412A2 (pt) método para medir reatividade de fviii
CL2021000635A1 (es) Composición sólida que comprende un componente oleoso comprendiendo uno o más aceites y un componente lipídico comprendiendo uno o más lípidos; su método de preparación (div. sol. 202000918).
BR112016001919A2 (pt) composição cosmética e processo de tratamento cosmético
CL2018002548A1 (es) Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
CL2016001375A1 (es) Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo.
AR107782A1 (es) Formulación gonadotropina líquida estable
BR112018000257A2 (pt) célula hospedeira, método para produzir um haa, uso de uma célula hospedeira, método para produzir uma célula hospedeira, célula, preparação de haa, método para produzir uma composição de ácido graxo e composição de ácido graxo
BR112018009618A2 (pt) processo para fabricação de uma dispersão aquosa compreendendo farelo de mostarda, emulsão de óleo em água e processo de fabricação de uma emulsão de óleo em água
MX2017011934A (es) Formas solidas de menaquinoles.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023012318-2 PROTOCOLO 870230052901 EM 20/06/2023 16:54.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements